These studies demonstrated that ALK TKIs combined with MEK TKIs targeting ALK-positive lung cancer cells have superior efficiency at suppressing cell growth, which provides an alternative approach for treating ALK-positive patients. The gene discussed is MAP2K7; the disease is lung carcinoma.